Vascular access in haemodialysis: Strengthening the Achilles' heel

Nature Reviews Nephrology

Volumn 9, Issue 6, 2013, Pages 348-357

  Riella, Miguel C ^a   Roy Chaudhury, Prabir ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; DESMIN; ELASTASE; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PADGEM PROTEIN; PRT 201; RAPAMYCIN; RETINOBLASTOMA PROTEIN; SCATTER FACTOR; UNCLASSIFIED DRUG; VIMENTIN;

ANGIOPLASTY; ARTERIOVENOUS FISTULA; ARTERY ANASTOMOSIS; BLOOD FLOW; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR THERAPEUTIC DEVICE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; GERIATRIC CARE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; OXIDATIVE STRESS; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; TISSUE ENGINEERING; VASCULAR ACCESS; VEIN THROMBOSIS;

ARTERIOVENOUS SHUNT, SURGICAL; GRAFT OCCLUSION, VASCULAR; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; VASCULAR GRAFTING;

EID: 84878600239     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.76     Document Type: Review

References (123)

1. Parker, T. F. 3rd, Glassock, R. J. & Steinman, T. I. Conclusions, consensus, and directions for the future. Clin. J. Am. Soc. Nephrol. 4 (Suppl. 1), S139-S144 (2009).
2. Rooijens, P. P. et al. Autogenous radial-cephalic or prosthetic brachial-antecubital forearm loop AVF in patients with compromised vessels? A randomized, multicenter study of the patency of primary hemodialysis access. J. Vasc. Surg. 42, 481-486 (2005).
3. Roy-Chaudhury, P., Sukhatme, V. P. & Cheung, A. K. Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J. Am. Soc. Nephrol. 17, 1112-1127 (2006).
4. Roy-Chaudhury, P. & Lee, T. Vascular stenosis: Biology and interventions. Curr. Opin. Nephrol. Hypertens. 16, 516-522 (2007).
5. Lee, T. & Roy-Chaudhury, P. Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv. Chronic Kidney Dis. 16, 329-338 (2009).
6. Quinton, W., Dillard, D. & Scribner, B. H. Cannulation of blood vessels for prolonged hemodialysis. Trans. Am. Soc. Artif. Intern. Organs 6, 104-113 (1960).
7. Konner, K. History of vascular access for haemodialysis. Nephrol. Dial. Transplant. 20, 2629-2635 (2005).
8. Brescia, M. J., Cimino, J. E., Appel, K. & Hurwich, B. J. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N. Engl. J. Med. 275, 1089-1092 (1966).
9. Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. Am. J. Kidney Dis. 48 (Suppl. 1), S176-S247 (2006).
10. Tordoir, J. et al. EBPG on Vascular Access. Nephrol. Dial. Transplant. 22 (Suppl. 2), ii88-ii117 (2007).
11. Jindal, K. et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J. Am. Soc. Nephrol. 17, S1-S27 (2006).
12. The Renal Association. Clinical Practice Guidelines for Vascular Access for Haemodialysis [online], http://www.renal.org/clinical/guidelinessection/ vascularaccess.aspx#summary (2011).
13. Rayner, H. C. et al. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): Performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am. J. Kidney Dis. 44, 22-26 (2004).
14. Department of Health & Human Services Centers for Medicare & Medicaid Services. CMS launches "Fistula First" initiative to improve care and quality of life for hemodialysis patients [online], http://www.esrdnetwork18.org/pdfs/QI%20-%20FF%20Breakthrough%20Initiative/ CMSPressRelease.pdf (2004).
15. Lych, J. R., Mohan, S. & McClellan, W. M. Achieving the goal: Results from the Fistula First Breakthrough Initiative. Curr. Opin. Nephrol. Hypertens. 20, 583-592 (2011).
16. Fistula First. Arteriovenous fistula first [online], www.fistulafirst. org.
17. Lee, T. & Roy-Chaudhury, P. Improving incident fistula rates: A process of care issue. Am. J. Kidney Dis. 57, 814-817 (2011).
18. Slinin, Y. et al. Meeting KDOQI guideline goals at hemodialysis initiation and survival during the first year. Clin. J. Am. Soc. Nephrol. 5, 1574-1581 (2010).
19. Bradbury, B. D. et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin. J. Am. Soc. Nephrol. 2, 89-99 (2007).
20. Beathard, G. A., Arnold, P., Jackson, J. & Litchfield, T. Aggressive treatment of early fistula failure. Kidney Int. 64, 1487-1494 (2003).
21. Tordoir, J. H. et al. Prospective evaluation of failure modes in autogenous radiocephalic wrist access for haemodialysis. Nephrol. Dial. Transplant. 18, 378-383 (2003).
22. Schild, A. F. et al. Maturation and failure rates in a large series of arteriovenous dialysis access fistulas. Vasc. Endovascular Surg. 38, 449-453 (2004).
23. Clark, T. W. et al. Salvage of nonmaturing native fistulas by using angioplasty. Radiology 242, 286-292 (2007).
24. Dember, L. M. et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. JAMA 299, 2164-2171 (2008).
25. Allon, M. & Lok, C. E. Dialysis fistula or graft: The role for randomized clinical trials. Clin. J. Am. Soc. Nephrol. 5, 2348-2354 (2010).
26. Roy-Chaudhury, P. et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int. 59, 2325-2334 (2001).
27. Roy-Chaudhury, P. et al. Neointimal hyperplasia in early arteriovenous fistula failure. Am. J. Kidney Dis. 50, 782-790 (2007).
28. Roy-Chaudhury, P. et al. Cellular phenotypes in human stenotic lesions from haemodialysis vascular access. Nephrol. Dial. Transplant. 24, 2786-2791 (2009).
29. Stracke, S. et al. Increased expression of TGF-beta1 and IGF I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int. 61, 1011-1019 (2002).
30. Li, L. et al. Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol. Dial. Transplant. 22, 3139-3146 (2007).
31. Li, L., Terry, C. M., Shiu, Y. T. & Cheung, A. K. Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int. 74, 1247-1261 (2008).
32. Roy-Chaudhury, P. et al. Hemodialysis vascular access dysfunction: From pathophysiology to novel therapies. Blood Purif. 21, 99-110 (2003).
33. Roy-Chaudhury, P. & Lee, T. C. Vascular stenosis: Biology and interventions. Curr. Opin. Nephrol. Hypertens. 16, 516-522 (2007).
34. Weiss, M. F., Scivittaro, V. & Anderson, J. M. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am. J. Kidney Dis. 37, 970-980 (2001).
35. Kokubo, T. et al. CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J. Am. Soc. Nephrol. 20, 1236-1245 (2009).
36. Langer, S. et al. Chronic kidney disease aggravates arteriovenous fistula damage in rats. Kidney Int. 78, 1312-1321 (2010).
37. Lee, T. et al. Severe venous neointimal hyperplasia prior to dialysis access surgery. Nephrol. Dial. Transplant. 26, 2264-2270 (2011).
38. Wasse, H. et al. Inflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients. J. Vasc. Access 13, 168-174 (2012).
39. Lehoux, S., Castier, Y. & Tedgui, A. Molecular mechanisms of the vascular responses to haemodynamic forces. J. Intern. Med. 259, 381-392 (2006).
40. Lehoux, S. Redox signalling in vascular responses to shear and stretch. Cardiovasc. Res. 71, 269-279 (2006).
41. Castier, Y., Brandes, R. P., Leseche, G., Tedgui, A. & Lehoux, S. p47phox-dependent NADPH oxidase regulates flow-induced vascular remodeling. Circ. Res. 97, 533-540 (2005).
42. Krishnamoorthy, M. K. et al. Anatomic configuration affects the flow rate and diameter of porcine arteriovenous fistulae. Kidney Int. 81, 745-750 (2012).
43. Lee, T. et al. Standardized definitions for hemodialysis vascular access. Semin. Dial. 24, 515-524 (2011).
44. Huber, T. S. et al. Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access. J. Vasc. Surg. 36, 452-459 (2002).
45. Malovrh, M. Native arteriovenous fistula: Preoperative evaluation. Am. J. Kidney Dis. 39, 1218-1225 (2002).
46. Dixon, B. S., Novak, L. & Fangman, J. Hemodialysis vascular access survival: Upper-arm native arteriovenous fistula. Am. J. Kidney Dis. 39, 92-101 (2002).
47. Miller, P. E. et al. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int. 56, 275-280 (1999).
48. Wong, V. et al. Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Eur. J. Vasc. Endovasc. Surg. 12, 207-213 (1996).
49. Goodkin, D. A., Pisoni, R. L., Locatelli, F., Port, F. K. & Saran, R. Hemodialysis vascular access training and practices are key to improved access outcomes. Am. J. Kidney Dis. 56, 1032-1042 (2010).
50. Prischl, F. C. et al. Parameters of prognostic relevance to the patency of vascular access in hemodialysis patients. J. Am. Soc. Nephrol. 6, 1613-1618 (1995).
51. Basile, C. & Lomonte, C. The operating surgeon is the major determinant for a successful arteriovenous fistula maturation. Kidney Int. 72, 772 (2007).
52. Dixon, B S. Why don't fistulas mature? Kidney Int. 70, 1413-1422 (2006).
53. Lok, C. E. et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J. Am. Soc. Nephrol. 17, 3204-3212 (2006).
54. Wang, W. et al. Comorbidities do not influence primary fistula success in incident hemodialysis patients: A prospective study. Clin. J. Am. Soc. Nephrol. 3, 78-84 (2008).
55. Silva, M. B. Jr et al. A strategy for increasing use of autogenous hemodialysis access procedures: Impact of preoperative noninvasive evaluation. J. Vasc. Surg. 27, 302-307 (1998).
56. Beck, G. J. et al. Progress of the hemodialysis fistula maturation (HFM) study (SA-OR452). Presented at American Society of Nephrology Kidney Week 2011.
57. He, C. et al. Impact of the surgeon on the prevalence of arteriovenous fistulas. ASAIO J. 48, 39-40 (2002).
58. Lazarides, M. K. et al. Influence of surgeons' specialty on the selection of vascular access for hemodialysis treatment. Blood Purif. 20, 338-341 (2002).
59. O'Hare, A. M. et al. Impact of surgeon and surgical center characteristics on choice of permanent vascular access. Kidney Int. 64, 681-689 (2003).
60. Choi, K. L. et al. Impact of surgeon selection on access placement and survival following preoperative mapping in the "Fistula First" era. Semin. Dial. 21, 341-345 (2008).
61. Mishler, R. & Yevzlin, A. S. Outcomes of arteriovenous fistulae created by a U. S. interventional nephrologist. Semin. Dial. 23, 224-228 (2010).
62. Beathard, G. A. An algorithm for the physical examination of early fistula failure. Semin. Dial. 18, 331-335 (2005).
63. Asif, A., Roy-Chaudhury, P. & Beathard, G. A. Early arteriovenous fistula failure: A logical proposal for when and how to intervene. Clin. J. Am. Soc. Nephrol. 1, 332-339 (2006).
64. Asif, A. et al. Accuracy of physical examination in the detection of arteriovenous fistula stenosis. Clin. J. Am. Soc. Nephrol. 2, 1191-1194 (2007).
65. Leon, C. & Asif, A. Physical examination of arteriovenous fistulae by a renal fellow: Does it compare favorably to an experienced interventionalist? Semin. Dial. 21, 557-560 (2008).
66. Robbin, M. L. et al. Hemodialysis arteriovenous fistula maturity: US evaluation. Radiology 225, 59-64 (2002).
67. National Kidney Foundation. 2006 Updates: Clinical Practice Guidelines and Recommendations [online], http://www.kidney.org/professionals/kdoqi/pdf/12- 50-0210-JAG-DCP-Guidelines-VA-Oct06-SectionC-ofC.pdf
68. Patel, S. T., Hughes, J. & Mills, J. L. Sr. Failure of arteriovenous fistula maturation: An unintended consequence of exceeding dialysis outcome quality Initiative guidelines for hemodialysis access. J. Vasc. Surg. 38, 439-445 (2003).
69. Beathard, G. A., Settle, S. M. & Shields, M. W. Salvage of the nonfunctioning arteriovenous fistula. Am. J. Kidney Dis. 33, 910-916 (1999).
70. Beathard, G. A. Strategy for maximizing the use of arteriovenous fistulae. Semin. Dial. 13, 291-296 (2000).
71. Falk, A. Maintenance and salvage of arteriovenous fistulas. J. Vasc. Interv. Radiol. 17, 807-813 (2006).
72. Nasser, G. M., Nguyen, B., Rhee, E. & Achkar, K. Endovascular treatment of the "failing to mature" arteriovenous fistula. Clin. J. Am. Soc. Nephrol. 1, 275-280 (2006).
73. Tessitore, N. et al. Endovascular versus surgical preemptive repair of forearm arteriovenous fistula juxta-anastomotic stenosis: Analysis of data collected prospectively from 1999 to 2004. Clin. J. Am. Soc. Nephrol. 1, 448-454 (2006).
74. Lipari, G. et al. Outcomes of surgical revision of stenosed and thrombosed forearm arteriovenous fistulae for haemodialysis. Nephrol. Dial. Transplant. 22, 2605-2612 (2007).
75. Lee, T. et al. Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation. Clin. J. Am. Soc. Nephrol. 6, 575-581 (2011).
76. [No authors listed] III. NKF K/DOQI Clinical Practice Guidelines for Vascular Access: Update 2000. Am. J. Kidney Dis. 37 (Suppl. 1), S137-S181 (2001).
77. Kumbar, L., Karim, J. & Besarab, A. Surveillance and monitoring of dialysis access. Int. J. Nephrol. http://dx.doi.org/10.1155/2012/649735.
78. Tonelli, M., James, M., Wiebe, N., Jindal, K. & Hemmelgarn, B. Ultrasound monitoring to detect access stenosis in hemodialysis patients: A systematic review. Am. J. Kidney Dis. 51, 630-640 (2008).
79. Paulson, W. D. Blood flow surveillance of hemodialysis grafts and the dysfunction hypothesis. Semin. Dial. 14, 175-180 (2001).
80. Work, J. Role of access surveillance and preemptive intervention. Semin. Vasc. Surg. 24, 137-142 (2011).
81. Paulson, W. D., Moist, L. & Lok, C. E. Vascular access surveillance: An ongoing controversy. Kidney Int. 81, 132-142 (2012).
82. Paulson, W. D. & Work, J. Controversial vascular access surveillance mandate. Semin. Dial. 23, 92-94 (2010).
83. Allon, M. & Robbin, M. L. Questions about graft surveillance. Kidney Int. 68, 2401-2402 (2005).
84. Tessitore, N. et al. Adding access blood flow surveillance to clinical monitoring reduces thrombosis rates and costs, and improves fistula patency in the short term: A controlled cohort study. Nephrol. Dial. Transplant. 23, 3578-3584 (2008).
85. United States Renal Data System. USRDS 2010 Annual Data Report: Atlas of End-Stage Renal Disease in the United States [online], http://www.usrds.org/ 2010/view/default.asp (2010).
86. Richardson, A. I. 2nd et al. Should fistulas really be first in the elderly patient? J. Vasc. Access 10, 199-202 (2009).
87. Lazarides, M. K., Georgiadis, G. S., Antoniou, G. A. & Staramos, D. N. A meta-analysis of dialysis access outcome in elderly patients. J. Vasc. Surg. 45, 420-426 (2007).
88. Lok, C. E. et al. Arteriovenous fistula outcomes in the era of the elderly dialysis population. Kidney Int. 67, 2462-2469 (2005).
89. Staramos, D. N. et al. Patency of autologous and prosthetic arteriovenous fistulas in elderly patients. Eur. J. Surg. 166, 777-781 (2000).
90. Vachharajani, T. J. et al. Re-evaluating the Fistula First initiative in octogenarians on hemodialysis. Clin. J. Am. Soc. Nephrol. 6, 1663-1667 (2011).
91. Chan, M. R., Sanchez, R. J., Young, H. N. & Yevzlin, A. S. Vascular access outcomes in the elderly hemodialysis population: A USRDS study. Semin. Dial. 20, 606-610 (2007).
92. Perl, J. et al. Hemodialysis vascular access modifies the association between dialysis modality and survival. J. Am. Soc. Nephrol. 22, 1113-1121 (2011).
93. Pisoni, R. L. et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: An instrumental variable analysis. Am. J. Kidney Dis. 53, 475-491 (2009).
94. United States Renal Data System. USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States [online], http://www.usrds.org/ atlas.aspx (2012).
95. Allon, M. et al. Effect of change in vascular access on patient mortality in hemodialysis patients. Am. J. Kidney Dis. 47, 469-477 (2006).
96. Manson, R. J. et al. Arteriovenous fistula creation using the Optiflow vascular anastomosis device: A first in man pilot study. Semin. Dial. 26, 97-99 (2013).
97. Gore. GORE® Hybrid Vascular Graft [online], http://www.goremedical. com/hybrid (2013).
98. Vassalotti, J. A. et al. Fistula first breakthrough initiative: Targeting catheter last in fistula first. Semin. Dial. 25, 303-310 (2012).
99. Peden, E. K. et al. A multi-center, dose-escalation study of human type I pancreatic elastase (PRT 201) administered after arteriovenous fistula creation. J. Vasc. Access http://dx.doi.org/10.5301/jva.5000125.
100. Paulson, W. D. et al. Safety and efficacy of locally eluted sirolimus for prolonging AV graft patency (PTFE Graft plus Coll. R.) - first in man experience. Poster at American Society of Nephrology Kidney Week 2011.
101. Paulson, W. D. et al. Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: First human experience with a sirolimus-eluting collagen membrane (Coll-R). Nephrol. Dial. Transplant. 27, 1219-1224 (2012).
102. Nugent, H. M. et al. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: A safety and efficacy study in the pig. J. Vasc. Res. 39, 524-533 (2002).
103. Nugent, H. M. et al. Adventitial endothelial implants reduce matrix metalloproteinase 2 expression and increase luminal diameter in porcine arteriovenous grafts. J. Vasc. Surg. 46, 548-556 (2007).
104. Conte, M. S. et al. Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: The V HEALTH study. J. Vasc. Surg. 50, 1359.e1-1368.e1 (2009).
105. Conte, M. S., Nugent, H. M., Gaccione, P., Roy Chaudhury, P. & Lawson, J. H. Influence of diabetes and perivascular allogeneic endothelial cell implants on arteriovenous fistula remodeling. J. Vasc. Surg. 54, 1383-1389 (2011).
106. Scheller, B. et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med. 355, 2113-2124 (2006).
107. Tepe, G. et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N. Engl. J. Med. 358, 689-699 (2008).
108. Katsanos, K. et al. Drug-coated balloon angioplasty in hemodialysis access. Presented at the 2011 38th Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium).
109. Morice, M. C. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773-1780 (2002).
110. Stone, G. W. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 221-231 (2004).
111. Stone, G. W. et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356, 998-1008 (2007).
112. Rotmans, J. I. et al. Sirolimus-eluting stents to abolish intimal hyperplasia and improve flow in porcine arteriovenous grafts: A 4 week follow-up study. Circulation 111, 1537-1542 (2005).
113. Tay, K. et al. Prospective randomised controlled trial comparing drug eluting stent (DES) versus percutaneous transluminal angioplasty (PTA) for the treatment of hemodialysis arterio-venous graft (AVG) stenoses: Preliminary report [abstract 7]. J. Vasc. Interv. Radiol. 22 (Suppl.), S6 (2011).
114. Haskal, Z. J. et al. Stent graft versus balloon angioplasty for failing dialysis-access grafts. N. Engl. J. Med. 362, 494-503 (2010).
115. Salman, L. & Asif, A. Dialysis: The stent graft for stenosis: Let's appraise before we praise. Nat. Rev. Nephrol. 6, 503-504 (2010).
116. Salman, L. & Asif, A. Stent graft for nephrologists: Concerns and consensus. Clin. J. Am. Soc. Nephrol. 5, 1347-1352 (2010).
117. Peck, M., Gebhart, D., Dusserre, N., McAllister, T. N. & L'Heureux, N. The evolution of vascular tissue engineering and current state of the art. Cells Tissues Organs 195, 144-158 (2011).
118. Peck, M. K. et al. New biological solutions for hemodialysis access. J. Vasc. Access 12, 185-192 (2011).
119. L'Heureux, N. et al. Human tissue-engineered blood vessels for adult arterial revascularization. Nat. Med. 12, 361-365 (2006).
120. McAllister, T. N. et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: A multicentre cohort study. Lancet 373, 1440-1446 (2009).
121. L'Heureux, N., McAllister, T. N. & de la Fuente, L. M. Tissue-engineered blood vessel for adult arterial revascularization. N. Engl. J. Med. 357, 1451-1453 (2007).
122. Dahl, S. L. et al. Readily available tissue-engineered vascular grafts. Sci. Transl. Med. 3, 68ra9 (2011).
123. Lopez-Vargas, P. A. et al. Barriers to timely arteriovenous fistula creation: A study of providers and patients. Am. J. Kidney Dis. 57, 873-882 (2011).